Navigation Links
WuXi PharmaTech to Partner with Pharmacyclics
Date:11/15/2013

SHANGHAI, Nov. 15, 2013 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that its wholly owned subsidiary Shanghai SynTheAll (STA) Pharmaceutical Co., Ltd., has entered into a supply arrangement with Pharmacyclics, Inc. (Nasdaq: PCYC). This follows a successful multiple-year development and clinical manufacturing partnership that supported Pharmacyclics with the expedited New Drug Application submission and final approval by the U.S. Food & Drug Administration (FDA).  After an expedited review by the FDA, IMBRUVICA received approval on November 13, 2013, for treatment of patients with mantle cell lymphoma who have received at least one prior therapy.  This indication is based on overall response rate.  An improvement in survival or disease-related symptoms has not been established.  In the GMP pre-approval inspection of WuXi's manufacturing facilities in August, no Form 483 observations were issued by the FDA. 

IMBRUVICA is a first-in-class, oral therapy and is a new agent that inhibits a protein called Bruton's tyrosine kinase (BTK).  BTK is a key signaling molecule of the B-cell receptor signaling complex that plays an important role in the survival of malignant B cells.  IMBRUVICA blocks signals that tell malignant B cells to grow and divide uncontrollably.  IMBRUVICA has been granted three Breakthrough Therapy Designations by the FDA, a first for an oncology drug.  These designations are intended to expedite the development and review of drugs for serious or life-threatening conditions.  To date, nine Phase III clinical trials have been initiated with IMBRUVICA and 37
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. WuXi PharmaTech Announces Third-Quarter 2013 Results
2. WuXi PharmaTech Announces Licensing Agreement for Patient-Derived Xenograft Models with Mayo Clinics Center for Individualized Medicine
3. Zacks.com featured expert Kevin Matras highlights: Core Laboratories NV, Invesco Ltd., Medtronic, Inc., Willbros Group Inc. and WuXi PharmaTech Inc.
4. WuXi PharmaTech Schedules First-Quarter 2013 Earnings Release
5. Breckenridge announces agreement with Aptalis Pharmatech to market Propranolol Hydrochloride Extended-Release Capsules
6. WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"
7. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
8. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
9. WuXi PharmaTech Schedules Fourth-Quarter 2012 Earnings Release
10. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
11. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... VEGAS , March 26, 2015 Zimmer ... Vivacit-E ® Advanced Bearing Technology with ... A paper published earlier this month reported that, ... Vivacit-E Advanced Bearing Technology featuring Vitamin E ... maintained a significant wear rate reduction of 95 percent, ...
(Date:3/26/2015)... WASHINGTON , March 26, 2015 Even ... anniversary of the Food and Drug Administration,s landmark approval ... from 11 members of Congress calling on the Agency ... approving a first-ever medical treatment for women,s most common ... 26 FDA-approved medical treatment options for sexual dysfunction – ...
(Date:3/26/2015)... , March 26, 2015 ... and Drug Safety Software Market by Functionality (Adverse Event ... based (SAAS)), End-user (Pharma & Biotech Companies, CROs, ... MarketsandMarkets, the Pharmacovigilance and Drug Safety Software Market ... 6.5% during 2014-2019, and is expected to reach ...
Breaking Medicine Technology:Zimmer Announces New Testing Milestone For Vitamin E Advanced Bearing Technology 2Zimmer Announces New Testing Milestone For Vitamin E Advanced Bearing Technology 3Even The Score Marks 17th Viagra Anniversary with Release of New Letter from Members of Congress to FDA Calling for Equity in Sexual Health 2Even The Score Marks 17th Viagra Anniversary with Release of New Letter from Members of Congress to FDA Calling for Equity in Sexual Health 3Even The Score Marks 17th Viagra Anniversary with Release of New Letter from Members of Congress to FDA Calling for Equity in Sexual Health 4Pharmacovigilance and Drug Safety Software Market Worth $154.1 Million by 2019 2Pharmacovigilance and Drug Safety Software Market Worth $154.1 Million by 2019 3Pharmacovigilance and Drug Safety Software Market Worth $154.1 Million by 2019 4
... a corporate mission of saving 100,000 more lives each year, ... leading manufacturer of medical devices and software for treating cancer ... expand its corporate branding efforts by tapping advertising agency DeVito/Verdi ... will be handled by the New York City-based agency,s San ...
... May 9, 2011 NxStage Medical, Inc. (Nasdaq: ... innovative dialysis products, today expressed its support for ... educate U.S. Congressional policymakers and their advisors about ... hemodialysis. (Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO) On ...
Cached Medicine Technology:Leading Medical Device and Software Manufacturer Looks to Build Its Brand With DeVito/Verdi 2Leading Medical Device and Software Manufacturer Looks to Build Its Brand With DeVito/Verdi 3NxStage® Supports Initiative by Patient Advocacy Groups to Educate Policymakers about the Benefits of Frequent Home Hemodialysis 2
(Date:3/26/2015)... (PRWEB) March 26, 2015 Behavioral ... consulting firm, announced the release of BathroomMap® , ... to increase access to public restrooms for travelers, especially ... bathroom apps, BathroomMap does not facilitate a paid, social ... to identify and rate local establishments that have clean, ...
(Date:3/26/2015)... March 26, 2015 Saving Moses is ... it is most needed but least available. As one ... to six clinics in the Benguela province of Angola ... During a recent visit to their clinics, staff employed ... mothers and their babies in a nation the The ...
(Date:3/26/2015)... March 26, 2015 The Life ... “Introduction to Hyperbaric Medicine” course, which is accredited ... (UHMS) and the National Board of Diving & ... 40-hour course 4 times a year at several ... NY tri-state region; registration is available on-line at: ...
(Date:3/26/2015)... March 26, 2015 BioPlus ... leading innovative specialty pharmacies, announces the promotion of ... Vice President of Pharmaceutical Relations. In this position, ... with our pharmaceuticals partners and providing key leadership ... of BioPlus’ expansion. , “Over the past ...
(Date:3/26/2015)... Md. (PRWEB) March 26, 2015 ... supports the Patients’ Access to Treatments Act (PATA) ... this week by Reps. David B. McKinley (R-WV) ... will limit cost-sharing requirements for medications placed in ... accessible by reducing patients’ out-of-pocket expenses. , This ...
Breaking Medicine News(10 mins):Health News:New Bathroom Finder App, BathroomMap®, Helps People with Medical Needs Who Urgently Need a Bathroom When Traveling 2Health News:New Bathroom Finder App, BathroomMap®, Helps People with Medical Needs Who Urgently Need a Bathroom When Traveling 3Health News:Saving Moses Utilized Photography in an Effort to Engage Mothers and Their Babies on a Recent Visit to Angola 2Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 2Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 3Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 4Health News:BioPlus Specialty Pharmacy Expands Executive Team with New Position, Naming Sharon Ferrer as Vice President of Pharmaceutical Relations 2Health News:Pulmonary Hypertension Association Part of Coalition Supporting the Patients’ Access to Treatments Act 2
... Magazine for a poll it was astonishing that Britons were ... 50% of them said that they believe in possessing mind-reading ... 43% said that they could read others' thoughts or had ... they had dreamt of an event before it occurred, 26% ...
... Researcher Linda Mansfield Michigan State University is a part ... at the role of parasitic worms// in treatment of ... of a more than $10 million National Institutes of ... Research Network of laboratories launched by the National Institutes ...
... Scientists in Japan have developed robotic hands, which they ... ,The artificial hands, developed by Yukiyasu Kamitani and ... based on real-time functional magnetic resonance imaging (fMRI) of ... Scientist. ,Researchers from the ATR Computational Neuroscience ...
... Hospital was suspended a she removed the properly functioning kidney ... found him guilty and suspended him for a period of ... that the French surgeon, Mr Blanchard’s conduct was inappropriate, unprofessional ... ,He said that he had not read the ...
... services in various hospitals affiliated to GSVM medical college ... against the OBC quota in elite educational institutions entered ... and students were continuing with the protest against Centre's ... in higher centres of learning, representatives of agitating doctors ...
... that milk chocolate containing caffeine has been good for ... times. ,Hence, chocolate lovers were found ... ,Adding value to the above study, an under graduate ... Raudenbush, Wheeling Jesuit University has done recently a research, ...
Cached Medicine News:Health News:Parasitic Worms Could Be Used To Treat Bowel Disease 2
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
... assay method for the semi-quantitative determination ... in human serum. The results of ... as an aid in the diagnosis ... associated with elevated anti-neutrophil cytoplasmic antibodies ...
... The determination of Ang II ... monitoring the pharmacological effect and ... of angiotensin converting enzyme inhibitors ... receptor antagonists as well as ...
... antigen test is a visual ... presumptive qualitative detection of Respitory ... specimens in neonatal and pediatric ... test has a built-in procedural ...
Medicine Products: